We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Therapeutic Antibodies – Multimedia

Monoclonal Antibodies: Making Cancer a Target content piece image
Video

Monoclonal Antibodies: Making Cancer a Target

Monoclonal antibodies, like the drugs Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxin (rituximab), are effective in treating a wide range of cancer types such as lung cancer, breast cancer, lymphoma, and others. By binding to cancer antigens, monoclonal antibodies mark the cells for destruction by the immune system. Clinical trials of more monoclonal antibodies for additional cancer types are ongoing.
Biologics Characterization Answers: Simple and Streamlined content piece image
eBook

Biologics Characterization Answers: Simple and Streamlined

Download this free eBook for articles, webinars and solution guides to help you extend your analytical capabilities, drive lab throughput and streamline your workflows.
Major Milestones in Therapeutic Antibody Engineering content piece image
Listicle

Major Milestones in Therapeutic Antibody Engineering

In this up-to-date list of milestones in therapeutic antibody engineering, you can learn about the first FDA-approved therapeutic antibody, the discovery of phage display libraries, bispecific antibodies and more.
10 Modern Milestones in Cancer Research content piece image
Listicle

10 Modern Milestones in Cancer Research

This list highlights ten major milestones within the field of cancer research since the year 2000.
What Are Antibody–Drug Conjugates (ADCs)? content piece image
Video

What Are Antibody–Drug Conjugates (ADCs)?

Antibody–drug conjugates or ADCs represent an innovative therapeutic application that combines the unique properties of monoclonal antibodies (mAbs) with the potent cell killing activity of cytotoxic small molecule drugs.
Is your Therapeutic Protein Characterization Pipeline Ready for the Future? content piece image
eBook

Is your Therapeutic Protein Characterization Pipeline Ready for the Future?

Download these eBooks to learn how BioPharma Compass helps you rise to this challenge by providing tools for CFR21 compliance and advanced support for high resolution subunits.
Targeting Tumors: Challenges of Antibody-Drug Conjugates content piece image
Video

Targeting Tumors: Challenges of Antibody-Drug Conjugates

More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor.

Anti-CelTOS Transmission Blocking Activity in vivo and in vitro against P. falciparum by Epitope-specific Monoclonal Antibodies  content piece image
Poster

Anti-CelTOS Transmission Blocking Activity in vivo and in vitro against P. falciparum by Epitope-specific Monoclonal Antibodies

The presence of CelTOS mAb significantly inhibited oocyst development in mosquitoes in both in vivo and in vitro assays. Importantly, the experimental results with an innovative in vivo humanized mouse model confirmed that circulating anti-CelTOS antibody effectively inhibits P. falciparum ookinete development to oocyst in mosquitoes. These results support the development of CelTOS as a transmission blocking vaccine.
Therapeutic Antibodies: Antibody-Drug Conjugates content piece image
Video

Therapeutic Antibodies: Antibody-Drug Conjugates

This is the third video in a three-part series of animations about therapeutic antibodies. This video focuses on antibody-drug conjugates.
Therapeutic Antibodies: Mechanism of Action content piece image
Video

Therapeutic Antibodies: Mechanism of Action

This is the second video in a three-part series of animations about therapeutic antibodies. This video focuses on antibody 'mechanism of action'.
Advertisement